The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer
The Korean Journal of Internal Medicine
; : 449-455, 2013.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-212579
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS:
Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC.METHODS:
We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups a short SER group ( 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy.RESULTS:
Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed.CONCLUSIONS:
Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
Full text:
Available
Health context:
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Other Respiratory Diseases
/
Trachea, Bronchus, Lung Cancers
Database:
WPRIM (Western Pacific)
Main subject:
Time Factors
/
Chi-Square Distribution
/
Odds Ratio
/
Proportional Hazards Models
/
Retrospective Studies
/
Treatment Outcome
/
Kaplan-Meier Estimate
/
Small Cell Lung Carcinoma
/
Chemoradiotherapy
/
Lung Neoplasms
Type of study:
Etiology study
/
Observational study
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
The Korean Journal of Internal Medicine
Year:
2013
Document type:
Article